Description
Measure Potency and Stability of Biologics that Bind and Activate FcyRIIa-H
Antibody-dependent cell-mediated phagocytosis (ADCP) is an important mechanism of action (MOA) of therapeutic antibodies. In vivo, ADCP can be mediated by monocytes, macrophages, neutrophils and dendritic cells via FcγRIIa, FcγRI and FcγRIIIa. While all three receptors can participate in ADCP, FcγRIIa is believed to be the predominant Fcγ receptor involved in this process.
The FcγRIIa-H ADCP Reporter Bioassay is a biologically relevant MOA-based assay that can be used to measure the potency and stability of antibodies and other biologics that specifically bind and activate FcγRIIa. The assay consists of Jurkat cells stably expressing human FcγRIIa-H (the high-affinity H131 variant) and NFAT-induced luciferase.
The bioassay workflow is simple and robust, compatible with 96-well and 384-well plate formats, and unlike traditional primary cell-based assays, amenable for use in quality-controlled drug development settings.
